Merck Serono Extends CNS Collaboration With Newron, Invests In Israel
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck Serono's revised deal with Newron gives the latter a license to develop two additional compounds, with Merck holding a buy-back option.